With increasing clinical use, radiotherapy (RT) has been considered reliable and effective method for hepatocellular carcinoma (HCC) treatment, depending on extent of disease and patient characteristics. RT for HCC can improve therapeutic outcomes through excellent local control, downstaging, conversion from unresectable to resectable status, and treatments of unresectable HCCs with vessel invasion or multiple intrahepatic metastases. In addition, further development of modern RT technologies, including image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and stereotactic body radiotherapy, has expanded the indication of RT. An essential feature of IGRT is that it allows image guidance therapy through in-room images obtained during radiation delivery. Compared with 3D-conformal RT, distinctions of IMRT are inverse treatment planning process and use of a large number of treatment fields or subfields, which provide high precision and exquisitely conformal dose distribution. These modern RT techniques allow more precise treatment by reducing inter- and intra-fractional errors resulting from daily changes and irradiated dose at surrounding normal tissues. More recently, particle therapy has been actively investigated to improve effectiveness of RT. This review discusses modern RT strategies for HCC, as well as optimal selection of RT in multimodal approach for HCC.
Citations
Citations to this article as recorded by
The Rac1-USP11 feedback amplification loop: a radiation-activated engine driving radioresistance in hepatocellular carcinoma Kaixiao Zhou, Yabo Jiang, Jiahao Guo, Haobo Zhang, Yuhao Hu, Xuanyu Meng, Yecheng Li, Shaohua Wei, Jian Wang, Xubiao Wei, Shuqun Cheng, Jianping Cao, Yang Jiao British Journal of Cancer.2026; 134(3): 391. CrossRef
Transarterial Chemoembolization Alone Versus Combined With Radiation Therapy as First-Line Therapy for Early-Stage Single Hepatocellular Carcinoma Hye In Lee, Jinhong Jung, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Sang Min Yoon International Journal of Radiation Oncology*Biology*Physics.2026; 125(3): 841. CrossRef
PLAC8 Variant‐Informed Multi‐Omics and AI Model for Survival Prediction in Advanced HCC Treated With Radiotherapy Plus Targeted Therapy and PD‐1 Inhibitors Jing Ren, Qingsong Luo, Zunyun Tan, Qiubing Zhang, Fang Gou, Hao Chi Human Mutation.2026;[Epub] CrossRef
A Bismuth‐Based Metal‐Phenolic Nanocoordinator Blocks TGF‑β to Reverse Immunosuppression for Potentiated Hepatocellular Carcinoma Radioimmunotherapy Fengfeng Xiao, Shengni Hua, Fei Liu, Ziliang Yan, Zhengsheng Yi, Yanxia Xu, Haichuan Peng, Jing Xiao, Yongjun Peng, Liewei Wen, Yunlu Dai Advanced Functional Materials.2026;[Epub] CrossRef
Effect of Narrow-Margin Hepatectomy Combined with Intraoperative Radiotherapy on Long-Term Prognosis of Patients with Centrally Located Hepatocellular Carcinoma: A Propensity Score Matching Analysis Changcheng Tao, Liguo Liu, Nan Hu, Hongwei Wang, Kai Zhang, Yue Liu, Fan Wu, Liming Wang, Weiqi Rong, Jianxiong Wu Journal of Hepatocellular Carcinoma.2025; Volume 12: 261. CrossRef
Microenvironment-triggered copper peroxide and tannic acid cooperatively iron-coordinated nanocomposites for oxidative stress-enhanced radiotherapy of hepatocellular carcinoma Zipeng Lei, Jiaqi Liao, Huiqin Yao, Xiaoting Zhou, Chun Yang, Qihui Wang, Hailong Jin, Xiao He, Qing Zhang, Yan Zu Nano Today.2025; 63: 102771. CrossRef
Report from the 26th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Hepatocellular and Biliary Tract Cancer, Saskatoon, Saskatchewan, 17–18 October 2024 Deepti Ravi, Shahid Ahmed, Blaire Anderson, Brady Anderson, Bryan Brunet, Haji Chalchal, Arun Elangovan, Georgia Geller, Vallerie Gordon, Branawan Gowrishankar, Edward Hardy, Mussawar Iqbal, Duc Le, Richard Lee-Ying, Shazia Mahmood, Karen Mulder, Maged Na Current Oncology.2025; 32(7): 398. CrossRef
Effects of three-dimensional conformal radiotherapy and image-guided radiotherapy on patients with liver cancer F. Xu, P. Xu International Journal of Radiation Research.2025; 23(3): 563. CrossRef
A review of deep learning approaches for multimodal image segmentation of liver cancer Chaopeng Wu, Qiyao Chen, Haoyu Wang, Yu Guan, Zhangyang Mian, Cong Huang, Changli Ruan, Qibin Song, Hao Jiang, Jinghui Pan, Xiangpan Li Journal of Applied Clinical Medical Physics.2024;[Epub] CrossRef
Dual-doped metalloporphyrin MOFs-based nanoagent increases low-dose radiotherapy efficacy by apoptosis-ferroptosis for hepatocellular carcinoma Xinxin Wang, Jianmin Zhou, Yanlin Zhu, Can Yu, Di Sun, Yuanfei Yao, Lili Feng, Piaoping Yang, Yang Zhou Chemical Engineering Journal.2024; 501: 157645. CrossRef
Autophagy-based therapy for hepatocellular carcinoma: from standard treatments to combination therapy, oncolytic virotherapy, and targeted nanomedicines Fereshteh Rahdan, Fatemeh Abedi, Hassan Dianat-Moghadam, Maryam Zamani Sani, Mohammad Taghizadeh, Effat Alizadeh Clinical and Experimental Medicine.2024;[Epub] CrossRef
Prognostic value of lymphocyte subset levels in hepatocellular carcinoma following conventionally fractionated vs. stereotactic body radiotherapy Si-Tong Wang, Yi-Xing Chen, Yu-Nan Gao, Ping Yang, Qian-Qian Zhao, Zhao-Chong Zeng, Yuan Zhuang Hepatoma Research.2024;[Epub] CrossRef
Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial–Mesenchymal Transition and Metastasis Yueh-Shan Weng, I-Tsang Chiang, Jai-Jen Tsai, Yu-Chang Liu, Fei-Ting Hsu International Journal of Radiation Oncology*Biology*Physics.2023; 115(3): 719. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Radionuclide‐Labeled Microspheres for Radio‐Immunotherapy of Hepatocellular Carcinoma Sai Yang, Chongjing Mu, Teng Liu, Pei Pei, Wenhao Shen, Yanxiang Zhang, Guanglin Wang, Lei Chen, Kai Yang Advanced Healthcare Materials.2023;[Epub] CrossRef
Advances in radiotherapy and immunity in hepatocellular carcinoma Yuhan Yang, Liting Xiong, Mengyuan Li, Ping Jiang, Junjie Wang, Chunxiao Li Journal of Translational Medicine.2023;[Epub] CrossRef
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma Hwa Kyung Byun, Changhwan Kim, Jinsil Seong Clinical and Molecular Hepatology.2023; 29(4): 945. CrossRef
Impact of Intrahepatic External Beam Radiotherapy in Advanced Hepatocellular Carcinoma Patients Treated with Tyrosine Kinase Inhibitors Myung Ji Goh, Hee Chul Park, Jeong Il Yu, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Dong Hyun Sinn, Moon Seok Choi Liver Cancer.2023; 12(5): 467. CrossRef
Large hepatocellular carcinoma treated with sequential SBRT and immunotherapy with anti-VEGF (Vascular Endothelial Growth Factor) therapy Bardia Bidarmaghz, Marwan Idrees, Yoo Young Lee, Peter Hodgkinson BMJ Case Reports.2023; 16(12): e256931. CrossRef
MiR-122 radiosensitize hepatocellular carcinoma cells by suppressing cyclin G1 Gang Xu, Shanshan Bu, Xiushen Wang, Hong Ge International Journal of Radiation Biology.2022; 98(1): 11. CrossRef
Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Jina Kim, Hwa Kyung Byun, Tae Hyung Kim, Sun Il Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Jinsil Seong Cancers.2022; 14(10): 2396. CrossRef
Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study Jian-Xu Li, Wen-Xiang Deng, Shi-Ting Huang, Xiao-Feng Lin, Mei-Ying Long, Jie Zhang, Ting-Shi Su, Li-Qing Li, Ya-Dan Pang, Chun-Feng Liang, Hong-Mei Zhou, Hai-Yan Lu, Shi-Xiong Liang, Bang-De Xiang Radiation Oncology.2022;[Epub] CrossRef
The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy Ying Xu, Yi Yang, Lu Li, Feng Ye, Xinming Zhao Frontiers in Oncology.2022;[Epub] CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis Han Li, Zhenying Wu, Jiali Chen, Ke Su, Lu Guo, Ke Xu, Tao Gu, Yi Jiang, Pan Wang, Hao Zeng, Hao Chi, Kun He, Yunwei Han Clinical and Experimental Medicine.2022; 23(5): 1537. CrossRef
Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study Nalee Kim, Jason Cheng, Wen-Yen Huang, Tomoki Kimura, Zhao Chong Zeng, Victor H.F. Lee, Chul Seung Kay, Jinsil Seong International Journal of Radiation Oncology*Biology*Physics.2021; 109(2): 464. CrossRef
Optimal Timing of Radiotherapy after Incomplete Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma Hwa Kyung Byun, Nalee Kim, Jinsil Seong Yonsei Medical Journal.2021; 62(5): 409. CrossRef
PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair Yinghai Xie, Changwei Liu, Yinci Zhang, Amin Li, Chong Sun, Rui Li, Yingru Xing, Minghong Shi, Qi Wang, Yi-Hsien Hsieh PLOS ONE.2021; 16(10): e0258817. CrossRef
Lupeol-Loaded Nanoparticles Enhance the Radiosensitivity of Hepatocellular Carcinoma by Inhibiting the Hyperactivation in Raf/Mitogen-Activated Protein Kinase and Phospatidylinositol-3 Kinase/mTOR Pathways Yinghai Xie, Changwei Liu, Shuping Zhou, Qi Wang, Xiaolong Tang Journal of Biomedical Nanotechnology.2021; 17(11): 2247. CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases Chang Liu, Yu‐Li Wang, Yong‐Yu Yang, Ning‐Ping Zhang, Chen Niu, Xi‐Zhong Shen, Jian Wu The FASEB Journal.2021;[Epub] CrossRef
MR-Guided Radiotherapy for Liver Malignancies Luca Boldrini, Stefanie Corradini, Cihan Gani, Lauren Henke, Ali Hosni, Angela Romano, Laura Dawson Frontiers in Oncology.2021;[Epub] CrossRef
ATF2-Induced Overexpression of lncRNA LINC00882, as a Novel Therapeutic Target, Accelerates Hepatocellular Carcinoma Progression via Sponging miR-214-3p to Upregulate CENPM Hua Ren, Zhi-cheng Wei, Yan-xia Sun, Chun-yan Qiu, Wen-jue Zhang, Wei Zhang, Tao Liu, Xu Che Frontiers in Oncology.2021;[Epub] CrossRef
KIF2C promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo Zhenya Gao, Huanxia Jia, Fang Yu, Hongfang Guo, Baoyu Li Experimental and Therapeutic Medicine.2021;[Epub] CrossRef
Silencing the Expression of Cyclin G1 Enhances the Radiosensitivity of Hepatocellular Carcinoma In Vitro and In Vivo by Inducing Apoptosis Gang Xu, Shanshan Bu, Xiushen Wang, Hong Ge Radiation Research.2021;[Epub] CrossRef
Delayed response to proton beam treatment of hepatocellular carcinoma Chee-Wai Cheng, Mitchell Machtay, Jennifer Dorth, Olga Sergeeva, Hangsheng Xia, chawan manaspon, Hanping wu, Renuka Iyer, Sandra Sexton, Wei Xin, Agata A Exner, Zhenghong Lee BJR|case reports.2020; 6(1): 20180125. CrossRef
Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma Nalee Kim, Jason Cheng, Inkyung Jung, Ja Der Liang, Yu Lueng Shih, Wen-Yen Huang, Tomoki Kimura, Victor H.F. Lee, Zhao Chong Zeng, Ren Zhenggan, Chul Seung Kay, Seok Jae Heo, Jong Yoon Won, Jinsil Seong Journal of Hepatology.2020; 73(1): 121. CrossRef
Circular RNA TUBD1 Acts as the miR-146a-5p Sponge to Affect the Viability and Pro-Inflammatory Cytokine Production of LX-2 Cells through the TLR4 Pathway Hao Niu, Li Zhang, Yu-Han Chen, Bao-Ying Yuan, Zhi-Feng Wu, Jason Chia-Hsien Cheng, Qin Lin, Zhao-Chong Zeng Radiation Research.2020; 193(4): 383. CrossRef
Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation Byung-Yoon Yun, Hye Won Lee, In Kyung Min, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(9): 2527. CrossRef
Huge Hepatocellular Carcinoma Exhibiting a Complete Response after Stereotactic Body Radiation Therapy Kyung In Shin, Byoung Kuk Jang, Jin Hee Kim, Jae Seok Hwang Journal of Liver Cancer.2020; 20(2): 167. CrossRef
Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry Young Eun Chon, Han Ah Lee, Jun Sik Yoon, Jun Yong Park, Bo Hyun Kim, In Joon Lee, Suk Kyun Hong, Dong Hyeon Lee, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee Journal of Liver Cancer.2020; 20(2): 135. CrossRef
External beam radiation therapy in a centenarian with primary liver cancer Zhen Meng, Feifei Gao, Chang Liu, Shengcai Huang, Kai Hu, Rensheng Wang Medicine.2020; 99(47): e22473. CrossRef
Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma Hwa Kyung Byun, Nalee Kim, Sangjoon Park, Jinsil Seong Strahlentherapie und Onkologie.2019; 195(11): 1007. CrossRef
Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation Chang Gon Kim, Hyun Woong Lee, Hye Jin Choi, Jung Il Lee, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Han Sang Kim, Kyung Hwan Kim, Seong Jin Choi, Yongun Kim, Kwan Sik Lee, Gyoung Min Kim, Man Deuk Kim, Jong Yoo Cancer Medicine.2019; 8(11): 5023. CrossRef
Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C Yeon Joo Kim, Jinhong Jung, Ji Hyeon Joo, So Yeon Kim, Jin Hyoung Kim, Young-Suk Lim, Han Chu Lee, Jong Hoon Kim, Sang Min Yoon Radiotherapy and Oncology.2019; 141: 95. CrossRef
Radiation-induced Myositis after Proton Beam Therapy to Huge Hepatocellular Carcinoma Jihye Kim, Gyu Sang Yoo, Dong Hyun Sinn, Hee Chul Park, Kwang Cheol Koh Journal of Liver Cancer.2019; 19(2): 136. CrossRef
Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study Beom Kyung Kim, Do Young Kim, Kwang-Hyub Han, Jinsil Seong, Jung Weon Lee PLOS ONE.2019; 14(10): e0223678. CrossRef
Knockdown of interferon‑stimulated gene 15 affects the sensitivity of hepatocellular carcinoma cells to norcantharidin Baoxiang Chen, Shuqiang Jin, Bin Bai, Zhi Li, Caifang Ni, Yansen Liu Experimental and Therapeutic Medicine.2019;[Epub] CrossRef
Novel thioureido-benzenesulfonamide derivatives with enaminone linker as potent anticancer, radiosensitizers and VEGFR2 inhibitors Mostafa M. Ghorab, Fatma A. Ragab, Helmy I. Heiba, Marwa G. El-Gazzar, Mostafa G.M. El-Gazzar Bioorganic & Medicinal Chemistry Letters.2018; 28(9): 1464. CrossRef
Proton beam therapy in apneic oxygenation treatment of an unresectable hepatocellular carcinoma: A case report and review of literature Yi-Lan Lin World Journal of Hepatology.2018; 10(10): 772. CrossRef
Background/Aims Portal vein invasion (PVI) is a poor prognostic factor in patients with hepatocellular carcinoma (HCC). We intended to compare the effects of surgical resection and transarterial chemoembolization (TACE) with additional radiation therapy (RT) in HCC patients with PVI.
Methods The subjects comprised 43 patients who underwent surgical resection for HCC with PVI without previous treatment and another 43 patients who received TACE followed by RT (TACE+RT) as initial treatment who were matched for Child-Pugh class, tumor size, and extent of PVI. Disease progression and death after the treatment were examined, and progression-free survival (PFS) and overall survival (OS) were compared between groups. Predisposing factors affecting OS were analyzed using univariate and multivariate analyses in HCC patients with PVI.
Results The subjects (Age [51, 24-74; median, range], Sex [81/13; male/female], Etiology [78/1/15; hepatitis B virus {HBV}/ hepatitis C virus {HCV}/non-HBV and non-HCV]) were followed for a median of 17 (2-68) months. There were no differences in clinical or tumor characteristics between the resection and TACE+RT groups. The cumulative PFS was not significantly different between groups. The median PFS was 5.6 and 4.0 months in the resection and TACE+RT groups, respectively. However, the cumulative OS was significantly longer in patients treated with resection than in those treated with TACE+RT (P=0.04). The median OS was 26.9 and 14.2 months in the resection and TACE+RT groups, respectively. Univariate and multivariate analyses revealed that surgical resection was an independent predictive factor for better survival outcome.
Conclusions Surgical resection might be an effective treatment in HCC patients with PVI.
Citations
Citations to this article as recorded by
Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment Sujin Jin, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jinhong Jung, Sang Min Yoon, Jonggi Choi Journal of Liver Cancer.2023; 23(1): 177. CrossRef
Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis Han Ah Lee, Yeon Seok Seo, In-Soo Shin, Won Sup Yoon, Hye Yoon Lee, Chai Hong Rim International Journal of Surgery.2022; 104: 106753. CrossRef
Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study Hye Kyung Hyun, Eun Ju Cho, Soo Young Park, Young Mi Hong, Soon Sun Kim, Hwi Young Kim, Nae-Yun Heo, Jung Gil Park, Dong Hyun Sinn, Wonseok Kang, Song Won Jeong, Myeong Jun Song, Hana Park, Danbi Lee, Yong Sun Lee, Sung Bum Cho, Chan Sik An, Hyung Jin Rhe Digestive Diseases and Sciences.2021; 66(7): 2427. CrossRef
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim Journal of Gastroenterology and Hepatology.2021; 36(5): 1317. CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Cancers.2021; 14(1): 67. CrossRef
Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation Byung-Yoon Yun, Hye Won Lee, In Kyung Min, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(9): 2527. CrossRef
Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion
Sojung Han, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Dai Hoon Han, Beom Kyung Kim Journal of Hepatocellular Carcinoma.2020; Volume 7: 403. CrossRef
Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study Dong‐won Lee, Hyung Joon Yim, Yeon Seok Seo, Seong Kyun Na, Seung Young Kim, Sang Jun Suh, Jong Jin Hyun, Sung Woo Jung, Young Kul Jung, Ja Seol Koo, Ji Hoon Kim, Jong Eun Yeon, Sang Woo Lee, Kwan Soo Byun, Soon Ho Um Liver International.2019; 39(6): 1109. CrossRef
Evaluating the role of RAD52 and its interactors as novel potential molecular targets for hepatocellular carcinoma Ping Li, YanZhen Xu, Qinle Zhang, Yu Li, Wenxian Jia, Xiao Wang, Zhibin Xie, Jiayi Liu, Dong Zhao, Mengnan Shao, Suixia Chen, Nanfang Mo, Zhiwen Jiang, Liuyan Li, Run Liu, Wanying Huang, Li Chang, Siyu Chen, Hongtao Li, Wenpu Zuo, Jiaquan Li, Ruoheng Zhan Cancer Cell International.2019;[Epub] CrossRef
Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion Jin Wook Chung Clinical and Molecular Hepatology.2018; 24(2): 135. CrossRef
Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies. Although transplant and surgical resection offer the best clinical outcomes, a limited number of patients are amenable to these surgical treatment options due to the advanced disease at presentation. Transarterial embolotherapies including conventional transarterial chemoembolization (cTACE), bland transarterial embolization (TAE), drug-eluting beads transarterial chemoembolization (DEB-TACE) and selective internal radiation therapy (SIRT) with Yttrium 90 (90Y) have played an increasingly important role for these patients with unresectable HCC. With a better understanding of different transarterial embolotherapies, more personalized and precise treatment should be implemented for these patients with unresectable HCC. In this review, the updated evidence on the current role of each embolotherapy in the treatment of HCC is summarized.
Citations
Citations to this article as recorded by
Efficacy and safety of transarterial chemoembolization plus donafenib with or without camrelizumab for unresectable hepatocellular carcinoma: a propensity score matching analysis Qi Zhang, Zhenwu Lei, Hezi Qing, Xingwu Xie Frontiers in Immunology.2026;[Epub] CrossRef
TACE Combined with Targeted Immunotherapy: A Strategy for Liver Transplantation Conversion and Survival Benefits in Patients with BCLC Stage B/C HCC Hanyuan Zhang, Xuzhi Zhang, Long Zhang, Shuai Wang, Yi Ma Journal of Hepatocellular Carcinoma.2026; Volume 13: 1. CrossRef
Development and application of AI enabled automated drug delivery system for TACE guided by DSA Tianming Du, Yin Xiong, Yalian Yu, Yi Wang, Yukang Li, Yan Huang, Xin Xiang, Bin Fu, Chen Li, Hongbo Wang, Meng Niu The Innovation Oncology.2026; 1(1): 100009. CrossRef
Efficacy and safety of transarterial chemoembolization and radiofrequency ablation plus tyrosine kinase inhibitors with or without programmed cell death protein-1 inhibitors for unresectable hepatocellular carcinoma Yue Chen, Luyao Jia, Yibo Sun, Zhenshun Wang, Yu Li, Jukun Wang, Chao Zhang, Chunjing Bian, Dongdong Lin, Tao Luo British Journal of Radiology.2026; 99(1184): 1569. CrossRef
Current Status and Progress of Hepatic Artery Perfusion Chemotherapy and Hepatic Artery Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma 少奇 祖 Advances in Clinical Medicine.2025; 15(02): 826. CrossRef
Assessing the Validity of the AASLD Surgical Treatment Algorithm in Patients with Early-Stage Hepatocellular Carcinoma Aryoung Kim, Byeong Geun Song, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Myung Ji Goh, Dong Hyun Sinn Gut and Liver.2025; 19(2): 265. CrossRef
The prognostic value of mitogen-activated protein kinase kinase in liver hepatocellular carcinoma by bioinformatics Shen Dong, Shen Jing, Jiao Qinshun, Wang Huaning, Zhu Rong Medicine.2025; 104(26): e42933. CrossRef
Viral oncogenesis and immune remodeling: Decoding the therapeutic potential of immune checkpoint inhibitors in virus-associated cancers Lihua Qi, Bai Hu, Canhui Cao, Ting Peng, Miaochun Xu, Shiyi Liu, Yashi Xu, Xiaojie Liu, Wencheng Ding, Li Li, Shitong Lin Biomedicine & Pharmacotherapy.2025; 191: 118515. CrossRef
Comparative study between Embosphere® and Marine gel® as embolic agents for chemoembolization of hepatocellular carcinoma Hyo-Cheol Kim, Jin Woo Choi World Journal of Gastrointestinal Oncology.2024; 16(1): 102. CrossRef
The predictive value of sarcopenia and myosteatosis in trans-arterial (chemo)-embolization treated HCC patients Jing Long, Xin Zhang, Wei Mi, Jianjun Shi, Hongwei Ren, Qiang Wang Aging.2024;[Epub] CrossRef
Synthesis and characterization of 3-in-1 multifunctional lipiodol-doped Fe3O4@Poly (diallyl isophthalate) microspheres for arterial embolization, chemotherapy, and imaging Piaoyi Chen, Qinglin Xiao, Zhaoxiong Guo, Wei Liang, Ou Liu, Liteng Lin, Yugang Huang, Kangshun Zhu, Guodong Ye Biomedical Materials.2024; 19(3): 035011. CrossRef
Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma Nojan Bajestani, Gavin Wu, Ahmed Hussein, Mina S. Makary Biomedicines.2024; 12(7): 1432. CrossRef
An In Vitro Comparative Study of Three Drug-Eluting Beads Loaded with Raltitrexed Enhao Lu, Jun Tie, Lingxiao Liu, Dong Lu, Weifu Lv, Xianyi Sha Cancer Biotherapy and Radiopharmaceuticals.2023; 38(9): 641. CrossRef
Benefits of stronger Neo‐Minophagen C in acute hepatitis after transarterial chemoembolization therapy for hepatomas Wen‐Chieh Huang, Yu‐Min Lin, Hsing‐Tao Kuo, Ming‐Jen Sheu, Yin‐Hsun Feng, I‐Che Feng, Chi‐Shu Sun, Ping‐Hsin Hsieh, Poh‐Poo Lim, Chi‐Hsing Chen Advances in Digestive Medicine.2023; 10(1): 8. CrossRef
Polydopamine-Coated Radiolabeled Microspheres for Combinatorial Radioembolization and Photothermal Cancer Therapy Manran Wu, Lei Zhang, Kexin Shi, Dongxu Zhao, Weipeng Yong, Lingling Yin, Ruizhe Huang, Guanglin Wang, Gang Huang, Mingyuan Gao ACS Applied Materials & Interfaces.2023; 15(10): 12669. CrossRef
In vitro comparative study of multimodal imaging nano-assembled microspheres with two clinical drug-eluting beads loaded with doxorubicin Yiwei He, Tiancheng Xu, Tingting Ding, Yuanchuan Gong, Hui Zeng, Zihan Xi, Yuanxin Ye, Ziyang Song, Ting Pan, Zhewei Zhang, Qian Ma, Lihua Li, Yuqing Zhang, Guoliang Shao Drug Delivery.2023;[Epub] CrossRef
Clinically Translatable Phosphonated Silica Microspheres for Selective Internal Radiation Therapy of Hepatocellular Carcinoma Yi Zhou, Jianxian Ge, Yun Gao, Zhe Yang, Mohammad Javad Afshari, Can Chen, Manran Wu, Lei Chen, Shuwang Wu, Guangxin Duan, Jianfeng Zeng, Mingyuan Gao Small Science.2023;[Epub] CrossRef
Hepatocellular Carcinoma from a Hepatologist's Perspective Giovanni A. Roldan, Jacquelin Blomker, Elizabeth S. Aby Seminars in Interventional Radiology.2023; 40(06): 524. CrossRef
Qilian Huaji decoction exerts an anti-cancer effect on hepatocellular carcinoma by upregulating miR-122 Yongsheng ZHOU, Dan ZHAO, Xuejun JIANG, Wen AN, Xiaoping GAO, Qingyong MA Food Science and Technology.2022;[Epub] CrossRef
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials Jihyun An, Seungbong Han, Ha Il Kim, Ju Hyun Shim Hepatology Communications.2022; 6(10): 2886. CrossRef
Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study Dong Hyun Sinn, Hye Won Lee, Yong-Han Paik, Do Young Kim, Yoon Jun Kim, Kang Mo Kim, Si Hyun Bae, Ji Hoon Kim, Yeon Seok Seo, Jae Young Jang, Byoung Kuk Jang, Hyung Joon Yim, Hyung Joon Kim, Byung Seok Lee, Bo Hyun Kim, In Hee Kim, Eun-Young Cho, Jung Il Digestive Diseases and Sciences.2021; 66(1): 315. CrossRef
Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study Hye Kyung Hyun, Eun Ju Cho, Soo Young Park, Young Mi Hong, Soon Sun Kim, Hwi Young Kim, Nae-Yun Heo, Jung Gil Park, Dong Hyun Sinn, Wonseok Kang, Song Won Jeong, Myeong Jun Song, Hana Park, Danbi Lee, Yong Sun Lee, Sung Bum Cho, Chan Sik An, Hyung Jin Rhe Digestive Diseases and Sciences.2021; 66(7): 2427. CrossRef
Delivery of Nanoconstructs in Cancer Therapy: Challenges and Therapeutic Opportunities Wen Shang Saw, Theebaa Anasamy, Yiing Yee Foo, Yee Chu Kwa, Chin Siang Kue, Chai Hong Yeong, Lik Voon Kiew, Hong Boon Lee, Lip Yong Chung Advanced Therapeutics.2021;[Epub] CrossRef
Optimized Loading of Idarubicin in CalliSpheres® Drug-Eluting Beads and Characterization of Release Profiles and Morphological Properties Enhao Lu, Guoliang Shao, Jingqin Ma, Yiwei He, Yuanchuan Gong, Zhiping Yan, Xianyi Sha Pharmaceutics.2021; 13(6): 799. CrossRef
Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Cancers.2021; 14(1): 67. CrossRef
Procedural description and prospective evaluation of short-term outcome for the use of prostatic artery embolization in dogs with carcinoma of the prostate William T. N. Culp, Eric G. Johnson, Michelle A. Giuffrida, Carrie A. Palm, Katherine A. Skorupski, Jenna H. Burton, Robert B. Rebhun, Jennifer L. Willcox, Michael S. Kent, Carlos O. Rodriguez, Craig B. Glaiberman Journal of the American Veterinary Medical Association.2021; 259(10): 1154. CrossRef
Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Current Oncology.2021; 28(1): 965. CrossRef
Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial Beom Kyung Kim, Do Young Kim, Hwa Kyung Byun, Hye Jin Choi, Seung-Hoon Beom, Hye Won Lee, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jinsil Seong, Kwang-Hyub Han International Journal of Radiation Oncology*Biology*Physics.2020; 107(1): 106. CrossRef
Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B Jeong-Ju Yoo, Su Jong Yu, Bora Lee, Eun Ju Cho, Jeong-Hoon Lee, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon Gut and Liver.2020; 14(3): 377. CrossRef
A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function Joon Yeul Nam, A Reum Choe, Dong Hyun Sinn, Jeong-Hoon Lee, Hwi Young Kim, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeong Min Lee, Jin Wook Chung, Sun Young Choi, Jeong Kyong Lee, Seung Yon Baek, Hye Ah Lee, Tae Hun Kim, Kwon Yoo BMC Cancer.2020;[Epub] CrossRef
Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies Mina S. Makary, Umang Khandpur, Jordan M. Cloyd, Khalid Mumtaz, Joshua D. Dowell Cancers.2020; 12(7): 1914. CrossRef
Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update Sirish A. Kishore, Raazi Bajwa, David C. Madoff Cancers.2020; 12(4): 791. CrossRef
Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization Min Young Baek, Jeong-Ju Yoo, Soung Won Jeong, Jae Young Jang, Yong Kwon Kim, Shin Ok Jeong, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Yong Jae Kim, Su Yeon Park The Korean Journal of Internal Medicine.2019; 34(6): 1223. CrossRef
Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model Eun Ju Cho, Su Jong Yu, Kyungmin Kim, Heki Cho, Young Youn Cho, Yun Bin Lee, Jeong-Hoon Lee, Yoon Jun Kim, Hyewon Youn, Jung-Hwan Yoon Journal of Bioenergetics and Biomembranes.2019; 51(2): 121. CrossRef
Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Young Eun Chon, Hana Park, Hye Kyung Hyun, Yeonjung Ha, Mi Na Kim, Beom Kyung Kim, Joo Ho Lee, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Seong Gyu Hwang, Kwang-Hyub Han, Kyu Sung Rim, Jun Yong Park Cancers.2019; 11(4): 509. CrossRef
Yttrium-90 Radioembolization: Current Clinical Practice and Review of the Recent Literature Tatulya Tiwari, Christopher Malone, Gretchen Foltz, Olaguoke Akinwande, Raja S. Ramaswamy Journal of Radiology Nursing.2019; 38(2): 86. CrossRef
Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis David Sooik Kim, Tae Seop Lim, Mi Young Jeon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Oidov Baatarkhuu, Seung Up Kim Digestive Diseases and Sciences.2019; 64(12): 3660. CrossRef
Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression Yu Young Joo, Jeong Won Jang, Sung Won Lee, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon Scientific Reports.2019;[Epub] CrossRef
Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review Nicolas Voizard, Milena Cerny, Anis Assad, Jean-Sébastien Billiard, Damien Olivié, Pierre Perreault, Ania Kielar, Richard K. G. Do, Takeshi Yokoo, Claude B. Sirlin, An Tang Insights into Imaging.2019;[Epub] CrossRef
Novel Albumin–Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization Jung Hee Kim, Dong Hyun Sinn, Jeong-Hoon Lee, Dongho Hyun, Sung Ki Cho, Sung Wook Shin, Young Chang, Yoon Jun Kim, Jung-Hwan Yoon, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi Digestive Diseases and Sciences.2018; 63(4): 1062. CrossRef
Falciform Ligament Artery Uptake on 99mTc MAA Planning Scan Before 90Y SIRT Confirmed by Retrospective SPECT/MRI Fusion Nils Große Hokamp, Carsten Kobe, James K. O’Donnell, Amit Gupta Clinical Nuclear Medicine.2018; 43(7): 522. CrossRef
Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor Song Yi Lee, Jin Woo Choi, Jae-Young Lee, Dae-Duk Kim, Hyo-Cheol Kim, Hyun-Jong Cho Drug Delivery.2018; 25(1): 1472. CrossRef
Antitumor Efficacy of Huqizhengxiao (HQZX) Decoction Based on Inhibition of Telomerase Activity in Nude Mice of Hepatocarcinoma Xenograft XiaoXiao Yu, Xue-Jun Lin, Shuang Wang, XiuHong Liu, WeiHua Li, Bu-Xin Kou, MengYin Chai, DeXi Chen, XiaoNi Liu, XiaoJun Wang Integrative Cancer Therapies.2018; 17(4): 1216. CrossRef
Practical Fingerprinting Localization for Indoor Positioning System by Using Beacons Santosh Subedi, Jae-Young Pyun Journal of Sensors.2017; 2017: 1. CrossRef
Background/Aims Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis. This study was undertaken to evaluate the therapeutic effects of concurrent chemo-radiation therapy in advanced hepatocellular carcinoma with portal vein thrombosis. Methods: A total of 54 patients with advanced hepatocellular carcinoma (TNM stage IVa) were enrolled. Nineteen patients were treated with external beam radiotherapy (4,500 cGy/ 5 weeks) and intrahepatic arterial 5-FU infusion (500 mg on 1-5 day and 30-35 day, respectively) via implanted chemoport. The others were treated with intrahepatic arterial cisplatin infusion (80 mg/m2). Results: In patients treated with concurrent chemo-radiation therapy, response rates at 2nd and 6th months were 42.1% and 26.3%, respectively. In patients treated with intrahepatic arterial cisplatin therapy, response rates at 2nd and 6th months were 2.9% and 0%, respectively. The median survival time was 11.6 months in concurrent chemo-radiation therapy and 4.8 months in intrahepatic arterial cisplatin infusion therapy. Concurrent chemo-radiation therapy produced better response rates and longer survival time than those of intrahepatic arterial cisplatin infusion therapy (p<0.05). Conclusions: Concurrent chemo-radiation therapy achieved favorable results in advanced hepatocellular carcinoma with portal vein thrombosis and can be considered as a treatment option for the management of advanced hepatocellular carcinoma.(Korean J Hepatol 2002;8:71-79)
First
Prev
